GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The company also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland. Show more

Joshua Dawson House, Dublin, D02 RY95, Ireland

https://www.ghres.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

911.8M

52 Wk Range

$7.98 - $19.51

Previous Close

$15.01

Open

$15.07

Volume

182,191

Day Range

$14.61 - $15.22

Enterprise Value

623.9M

Cash

288.5M

Avg Qtr Burn

-10.42M

Insider Ownership

26.78%

Institutional Own.

71.12%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
GH001 (inhalable mebufotenin) (5-MeO-DMT) Details Treatment Resistant Depression	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GH001 (inhalable mebufotenin) (5-MeO-DMT) Details Postpartum depression	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GH001 (inhalable mebufotenin) (5-MeO-DMT) Details Bipolar depression	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GH001 (inhalable mebufotenin) (5-MeO-DMT) Details Treatment Resistant Depression	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GH002 (IV mebufotenin) (5-MeO-DMT) Details Treatment Resistant Depression	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.